B. Riley Financial Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price

Capricor Therapeutics (NASDAQ:CAPR) had its price objective raised by equities research analysts at B. Riley Financial from $50.00 to $63.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. B. Riley Financial’s target price suggests a potential upside of 106.25% from the stock’s current price.

Several other equities research analysts also recently issued reports on CAPR. UBS Group set a $50.00 price objective on Capricor Therapeutics in a report on Monday, December 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a report on Tuesday. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Finally, Oppenheimer raised their price objective on Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.09.

Capricor Therapeutics Stock Performance

Shares of CAPR stock traded down $2.87 during trading hours on Friday, reaching $30.55. The company had a trading volume of 1,767,557 shares, compared to its average volume of 1,340,521. The company has a market capitalization of $1.69 billion, a P/E ratio of -17.05 and a beta of 0.37. Capricor Therapeutics has a twelve month low of $4.30 and a twelve month high of $40.37. The stock’s fifty day simple moving average is $25.66 and its 200 day simple moving average is $16.35.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, March 18th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, equities analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds have recently modified their holdings of the company. Farther Finance Advisors LLC acquired a new stake in Capricor Therapeutics during the 3rd quarter valued at $28,000. Parkside Financial Bank & Trust purchased a new position in shares of Capricor Therapeutics during the third quarter valued at $36,000. Russell Investments Group Ltd. grew its holdings in shares of Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 2,786 shares in the last quarter. ACT Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at $43,000. Finally, GoalVest Advisory LLC purchased a new stake in Capricor Therapeutics in the 4th quarter worth about $59,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: FDA resumed review of deramiocel and set an August decision window, reviving the pathway for approval and reducing some regulatory uncertainty. Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
• Positive Sentiment: Late-breaking HOPE-3 Phase 3 data presented at the 2026 MDA conference showed significant functional benefits for deramiocel in Duchenne muscular dystrophy — a clinical readout that supports the therapy’s commercial potential if approved. HOPE-3 Data Press Release
• Positive Sentiment: HC Wainwright reiterated a Buy rating on CAPR, which can provide support from buy-side interest and signal confidence to some investors. HC Wainwright Reiterates Buy Rating for Capricor Therapeutics
• Neutral Sentiment: Company filed its fourth-quarter and full-year 2025 results and provided a corporate update; the release contains financial details and operational commentary investors will parse for runway and milestones. Q4 & Full-Year 2025 Results
• Neutral Sentiment: Q4 2025 earnings call transcript and supplemental materials are available for detailed management commentary and Q&A — useful for assessing guidance, cash runway and commercialization planning. Earnings Call Transcript
• Neutral Sentiment: News outlets flagged “earnings on deck” coverage following the FDA review resumption — media attention can amplify both upside and downside moves depending on follow-up items. Investing.com Coverage
• Neutral Sentiment: Recent short-interest reports show anomalous “0 shares” figures and a 0.0 days-to-cover metric — likely data noise rather than a material shift in short positioning. (Multiple short-interest updates posted March 11–12.)
• Negative Sentiment: Q4 EPS missed consensus: CAPR reported a loss of ($0.62) vs. analysts’ ($0.51) estimate. An EPS miss amid a biotech story often triggers immediate selling as investors re-price near-term execution and funding risk. MarketBeat Earnings Coverage

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.